- Merck KGaA's 1st in class brain cancer drug cilengitide flunks Ph III
- Roche and MorphoSys go pivotal with early Alzheimer's drug
- Post-Inhibitex, BMS pins down hepatitis C options
- ANALYSIS: Disease foundations sharpen the knife to spread the wealth
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.